| 13060 |
17(R)-Resolvin D1
Exclusive |
|
528583-91-7 |
≥95%
|
|
✓ |
2008-12-18
|
141.253393133083
|
17-r-resolvin-d1
|
AT-RvD1; Aspirin-triggered-Resolvin D1; 17(R)-RvD1
|
EPAs DHAs resolvins inflammation antiinflammatory anti-inflammatory immune response aspirin LOXs 17R ATRvD1 17RRvD1 |
141.253393133083
|
| 90420 |
5(S),14(R)-Lipoxin B4
|
|
98049-69-5 |
>95%
|
|
|
2008-11-17
|
45.002811540823
|
5-s-14-r-lipoxin-b4
|
5(S),14(R)-LXB4
|
LXB4 trihydroxy fatty acids leukocyte activation LXA4 inflammation lipoxins inhibits inhibition inhibitiors |
45.002811540823
|
| 90415 |
5(S),6(R),15(R)-Lipoxin A4
|
|
171030-11-8 |
≥95%
|
|
|
2008-11-17
|
86.651298342541
|
5-s-6-r-15-r-lipoxin-a4
|
5(S),6(R),15(R)-LXA4; AT-Lipoxin A4; 15-epi Lipoxin A4
|
inflammations lipoxins aspirins ASA neutrophils inflammatory aspirins triggered |
86.651298342541
|
| 10005032 |
5(S),6(R)-7-trihydroxymethyl Heptanoate
|
|
- |
≥95%
|
|
|
2007-06-13
|
108.264972375691
|
5-s-6-r-7-trihydroxymethyl-heptanoate
|
BML-111
|
lipoxins metabolites arachidonic acids AA lipoxygenases A4 LXA4 chemotaxis neutrophils PMN leukotrienes B4 LTB4 FMLP analogs inhibition plymorphonuclear |
108.264972375691
|
| 90410 |
5(S),6(R)-Lipoxin A4
|
|
89663-86-5 |
≥95%
|
|
|
|
136.045439864003
|
5-s-6-r-lipoxin-a4
|
5(S),6(R)-LXA4; 5(S),6(R),15(S)-TriHETE
|
LXA4 lipoxins trihydroxy fatty acids leukocytes activation |
136.045439864003
|
| 10007737 |
5(S),6(R)-Lipoxin A4-d5
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
2009-04-09
|
45.540476519337
|
5-s-6-r-lipoxin-a4-d5
|
5(S),6(R)-LXA4-d5; 5(S),6(R),15(S)-TriHETE-d5
|
LXA4 lipoxins trihydroxy fatty acids leukocytes activation deuterated deuteriums MS LC mass spectrometry standards GC |
45.540476519337
|
| 10007271 |
5(S),6(R)-Lipoxin A4 Lipid Maps MS Standard
|
|
89663-86-5 |
≥95%
|
|
|
2009-02-18
|
43.257486187845
|
5-s-6-r-lipoxin-a4-lipid-maps-ms-standard
|
5(S),6(R),15(S)-TriHETE; 5(S),6(R)-LXA4
|
LXA4 lipoxins trihydroxy fatty acids leukocytes activation MS mass spectrometry standards |
43.257486187845
|
| 10033 |
5(S),6(R)-Lipoxin A4 methyl ester
|
|
97643-35-1 |
>95%
|
|
|
2004-04-01
|
67.310176795580
|
5-s-6-r-lipoxin-a4-methyl-ester
|
5(S),6(R)-LXA4 methyl ester; 5(S),6(R),15(S)-TriHETE methyl ester
|
LXA4ME LXA4-ME lipoxins trihydroxy fatty acids leukocytes activation prodrugs syoerixude generation esters |
67.310176795580
|
| 10049 |
5(S),6(S)-Lipoxin A4
|
|
- |
>95%
|
|
|
2004-06-29
|
115.163093922652
|
5-s-6-s-lipoxin-a4
|
5(S),6(S),15(S)-TriHETE; 5(S),6(S)-LXA4
|
LXA4 lipoxins trihydroxy fatty acids leukocytes activation 11-cis isomers |
115.163093922652
|
| 10878 |
7(R)-Maresin 1
New |
|
1268720-28-0 |
≥95%
|
|
|
2012-02-01
|
204.905314917127
|
7-r-maresin-1
|
7(R)-MaR1
|
docosahexaenoic acids DHA macrophages zymosan inflammation phagocytosis fatty brain retina murine peritonitis FITC 7(R) maresin 1 mar 1 |
204.905314917127
|
| 13161 |
7(S)-Maresin 1
Exclusive |
|
1268720-66-6 |
≥95%
|
|
✓ |
2010-08-19
|
88.116926167754
|
7-s-maresin-1
|
7(S)-MaR1
|
docosahexaenoic acids DHA macrophages zymosan A inflammation phagocytosis lipids zymosan-A peritoneum FITC-labeled FITC labeled mouse murine mice 7,14-dihydroxy 14S-hydroperoxy 887752-49-0 inflammation antiinflammatory anti-inflammation antiinflammation Docosahexaenoic Acid |
88.116926167754
|
| 10011453 |
Lipoxin A5
Exclusive |
|
110657-98-2 |
≥95%
|
|
✓ |
2008-11-17
|
55.738222836095
|
lipoxin-a5
|
LXA5
|
EPAs LXA4 LXB4 smooth muscle contraction lipoxins vasodilatory leukocytes pulmonary parenchymal LXAs |
55.738222836095
|